Info On What It Costs To Make Insulin API's Offshore (Courtesy of China's Gan & Lee Pharmaceuticals Ltd.)
When pharma companies refer to API ' s, they are referring to " Active Pharmaceutical Ingredients " (which is different from what an internet company means when they say API; to internet companies, the acronym API means " Application Programming Interface " ). Regardless, pharma API ' s are commonly made offshore in places like India, Malaysia, China and elsewhere because its cheaper for them and therefore helps their own bottom lines. Its unclear to me exactly how they manage issues including transporting the products across the world for some items which must be temperature-controlled, but if it fattens pharma ' s bottom...
Source: Scott's Web Log - May 1, 2023 Category: Endocrinology Tags: 2023 Biosimilar biosimilars BLA China COGS FDA Gan & Lee insulin Sandoz Source Type: blogs
Sanofi Joins The Ranks of $35/vial Insulin, Adds New Unbranded Insulin to Product Lineup
Yesterday, Sanofi U.S. made an announcement: Effective on July 1, 2022, the company will lower out-of-pocket cost of insulin for uninsured patients and expand access in underserved communities (in reality, the lower prices are available to anyone including those who have insurance deductibles to satisfy). The press release can be viewed athttps://www.news.sanofi.us/2022-06-29-Sanofi-to-lower-out-of-pocket-cost-of-insulin-for-uninsured-patients-and-expand-access-in-underserved-communities.Sanofi has been a laggard relative to its rivals Lilly and Novo Nordisk. For example, in 2019, both Lilly and Novo Nordisk each announced...
Source: Scott's Web Log - July 1, 2022 Category: Endocrinology Tags: Sanofi Aventis Sanofi-Aventis 2022 drug prices Euro API insulin insulin prices Source Type: blogs
Civica Rx: We're Entering the U.S. Insulin Biosimilar Business!
This morning, I woke up and unplugged my phone from its charger, and went to close Twitter (which I forgot to close last night before I went to bed) and at the top was a press release from Civica Rx. The press release is here: Civica to Manufacture and Distribute Affordable Insulinhttp://dlvr.it/SL0QZV The news was greeted as a welcome development by JDRF, Beyond Type 1 and the Helmsley Charitable Trust to name a few. The ADA said nothing formally about it as of 10:00 AM. In essence, Civica Rx says it plans to sell biosimilar versions of Lantus, Humalog and Novolog. As usual, there ' s a lot of details unpack her...
Source: Scott's Web Log - March 3, 2022 Category: Endocrinology Tags: 2022 Biocon Biosimilar biosimilars Civica Rx CivicaRx insulin Viatris Source Type: blogs
Some Key EASD News for T1D
This week, the European rival to the ADA Scientific Sessions known as EASD (which stands for the European Association for the Study of Diabetes) held its annual meeting, which was the organization ' s 57th Annual Meeting and it took place virtually (much like the ADA Scientific Sessions did this year) due to COVID-19. EASD was held from September 27, 2021 to October 1, 2021. In recent years, neither the ADA Scientific Sessions not the EASD Meetings have yielded many surprise findings or previously unknown product launches.My short summary is that Novo Nordisk is finally getting on the " smart pen " cap bandwagon, while riv...
Source: Scott's Web Log - October 1, 2021 Category: Endocrinology Tags: 2021 Bigfoot Unity Companion Medical EASD FTC insulin prices Lilly Medtronic diabetes Novo Nordisk rebate reform Smart Pen Caps Smart Pens Source Type: blogs
U.S. Patients Need U.S. FTC to Do More to Bring Rx Drug Prices Down to Earth
For a moment, try to answer the following question honestly:When are biosimilar insulins, even those which are designated by the FDA as " interchangable " with the innovator, MORE EXPENSIVE than the originator molecule the biosimilar is supposed to be a copy of? The correct answer is when a person with diabetes lives in the United States. It defies logic!In theory, the biosimilars should be cheaper because the work of developing, conducting clinical trials and whatnot is not the same to make a copy. The biosimilar doesn ' t have to go through the same process of conducting extensive three phases of clinical trial...
Source: Scott's Web Log - September 15, 2021 Category: Endocrinology Tags: Federal Trade Commission FTC PBM rebate reform rebates Source Type: blogs
U.S. Patients Need U.S. FTC to Do More to Bring Rx Drug Prices Down to Earth
For a moment, try to answer the following question honestly:When are biosimilar insulins, even those which are designated by the FDA as " interchangeable " with the innovator, MORE EXPENSIVE than the originator molecule the biosimilar is supposed to be a copy of? The correct answer is when a person with diabetes lives in the United States. It defies logic!In theory, the biosimilars should be cheaper because the work of developing, conducting clinical trials and whatnot is not the same to make a copy. The biosimilar doesn ' t have to go through the same process of conducting extensive three phases of clinical tria...
Source: Scott's Web Log - September 15, 2021 Category: Endocrinology Tags: Biosimilar biosimilars Federal Trade Commission FTC PBM rebate reform rebates Source Type: blogs
Making Sense of the Novo Nordisk-Walmart Partnership to Sell Some Discounted Insulin Analogues
On June 29, 2021, Walmart Inc. and the American business unit of Novo Nordisk A/S (which is based just outside of Princeton, New Jersey known as Novo Nordisk Inc.) dropped what was intended to be a news bombshell coming just as the ADA Scientific Sessions was coming to a close. In fact, the insulin makers had hardly any big news coming from the ADA Scientific Sessions themselves this year (in fact, Novo Nordiskacquired a UK-based company known as Ziylo in 2018 to use its technology to try and develop glucose-responsive insulin, but it still has a long while before it is ready for commercialization ... if ever), becaus...
Source: Scott's Web Log - July 15, 2021 Category: Endocrinology Tags: Aspart Novo Nordisk Novolog Walmart Source Type: blogs
Making Sense of the Novo Nordisk-Walmart Partnership to Sell Some Discounted Insulin Analogues
On June 29, 2021, Walmart Inc. and the American business unit of Novo Nordisk A/S (which is based just outside of Princeton, New Jersey known as Novo Nordisk Inc.) dropped what was intended to be a news bombshell coming just as the ADA Scientific Sessions was coming to a close. In fact, the insulin makers had hardly any big news coming from the ADA Scientific Sessions themselves this year or for the past several years (about the biggest news was from 2018 when, Novo Nordiskacquired a UK-based company known as Ziylo to use its technology to try and develop glucose-responsive insulin, but that still has a long whil...
Source: Scott's Web Log - July 15, 2021 Category: Endocrinology Tags: Aspart Novo Nordisk Novolog Walmart Source Type: blogs
More Games With U.S. Insulin Prices and Coupons (or why GoodRx works)
This week, I did something unplanned: I bought a vial of Lilly ' s " authorized generic " of its brand-name U-100 insulin analog usually branded as Humalog (insulin lispro rDNA origin) at my neighborhood Walgreens for just $68.38! The reason it was unplanned is because I already met the deductible for my insurance plan, so I hadn ' t expected to deal with this until it resets in January (maybe, I think my new plan covers it without having met the deductible but we ' ll see). But I had a script I last filled before I met the deductible, and the pharmacy sent a text telling me it was time to refill. In reality, I have i...
Source: Scott's Web Log - September 23, 2020 Category: Endocrinology Tags: Admelog Drug Channels drug prices GoodRx Humalog insulin Lilly lispro prescriptions rebates Sanofi Walgreens Source Type: blogs
More Games With U.S. Insulin Prices and Coupons (or why GoodRx works)
This week, I did something unplanned: I bought a vial of Lilly ' s " authorized generic " of its brand-name U-100 insulin analog usually branded as Humalog (insulin lispro rDNA origin) at my neighborhood Walgreens for just $68.38. The reason it was unplanned is because I already met the deductible for my insurance plan, so I hadn ' t expected to deal with this until it resets in January (maybe, I think my new plan covers it without having met the deductible but we ' ll see). But I had a script I last filled before I met the deductible, and the pharmacy sent a text telling me it was time to refill. In reality, I have insuli...
Source: Scott's Web Log - September 23, 2020 Category: Endocrinology Tags: Admelog Drug Channels drug prices GoodRx Humalog insulin Lilly lispro prescriptions rebates Sanofi Walgreens Source Type: blogs
More Games With U.S. Insulin Prices and Coupons
This week, I did something unplanned: I bought 2 vials of Lilly ' s " authorized generic " of its brand-name U-100 insulin analog branded as Humalog (insulin lispro rDNA origin) at my neighborhood Walgreens. The reason it was unplanned is because I already met the deductible for my insurance plan, so I hadn ' t expected to deal with this until it resets in January. But I had a script I last filled before I met the deductible, and the pharmacy sent a text telling me it was time to refill. In reality, I have insulin but its a different brand and a different pharmacy. But Walgreens wants a sale so it was telling me it is time...
Source: Scott's Web Log - September 23, 2020 Category: Endocrinology Tags: Admelog Drug Channels drug prices GoodRx Humalog insulin Lilly prescriptions rebates Sanofi Source Type: blogs
Are physicians allowed to be human?
I knew Friday was not going to be a good day. A leak in the ceiling of my family room. A pet who would need surgery. I was already stressed well before Friday. But at work, the issues started on Thursday with an osteoporotic patient for whom I had recommended Forteo, six weeks earlier. It […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - January 22, 2020 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/mark-lopatin" rel="tag" > Mark Lopatin, MD < /a > < /span > Tags: Physician Rheumatology Source Type: blogs
A new therapy for osteoporosis: Romosozumab
Osteoporosis is a condition in which bones become porous (less dense) and weaker. It affects 10 million people in the United States: approximately eight million women and two million men. As bone weakens, people are more likely to experience fractures, especially in the spine, hip, and forearm. This causes pain, diminishes a person’s ability to function, and reduces quality of life. Anything that can lower the risk of osteoporosis and fractures has major positive public health implications. That’s why a new drug called romosozumab is getting a lot of attention.
Which medications can help treat osteoporosis?
There are c...
Source: Harvard Health Blog - July 17, 2019 Category: Consumer Health News Authors: David M. Slovik, MD Tags: Bones and joints Menopause Osteoporosis Women's Health Source Type: blogs
My Trial With Sanofi's Admelog, The Biosimilar Version of Humalog
A while back Iblogged about the emergence of biosimilar insulin in the U.S., more than a decade after I studied the topic and discovered some troubling reasons none existed. Since then, in spite of top officials at the U.S. Department of Health and Human Services advocating for a more robust biosimilars market in the U.S., we have seen fewer rather than more, so that ' s not working out so well for the Trump Administration ' s promise to bring drug prices way down so far. In late 2018, Merck quietly pulled the plug on its own Lantus biosimilar which was to be branded as Lusduna Nexvue (see moreHERE for details). ...
Source: Scott's Web Log - April 9, 2019 Category: Endocrinology Tags: Eli Lilly and Company follow-on insulin analogs 2019 Admelog biosimilars generics Humalog insulin prices Medicare Sanofi Source Type: blogs
My Trial With Sanofi's Admelog, The Biosimilar Version of Humalog
A while back Iblogged about the emergence of biosimilar insulin in the U.S., more than a decade after I studied the topic and discovered some troubling reasons none existed. Since then, in spite of top officials at the U.S. Department of Health and Human Services advocating for a more robust biosimilars market in the U.S., we have seen fewer rather than more, so that ' s not working out so well for the Trump Administration ' s promise to bring drug prices way down so far. In late 2018, Merck quietly pulled the plug on its own Lantus biosimilar which was to be branded as Lusduna Nexvue (see moreHERE for details). ...
Source: Scott's Web Log - April 9, 2019 Category: Endocrinology Tags: Eli Lilly and Company follow-on insulin analogs 2019 Admelog biosimilars generics Humalog insulin prices Medicare Sanofi Source Type: blogs
